SEK 28.56
Key Takeaways
Risk factor
Resilient to price shocks
Profitability factor
Favourable analyst view
About
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value
Target Price
The average target price of VIMIAN.ST is 38 and suggests 33% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
